BioCryst Boosts HAE Franchise With Astria Acquisition, Guidance
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from BioCryst ( (BCRX) ) is now available.
BioCryst Pharmaceuticals, Inc. is a global biotechnology company focused on developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. Its lead product ORLADEYO (berotralstat) is the first oral, once-daily plasma kallikrein inhibitor, and the company is advancing a pipeline of oral small-molecule and injectable protein therapeutics targeting niche rare-disease markets.
In 2025, BioCryst achieved its first full-year profitability, as total revenues nearly doubled to $874.8 million and ORLADEYO net revenue climbed 38% to $601.8 million despite the October sale of its European ORLADEYO business to Neopharmed Gentili. The company streamlined operations with that divestiture, gained FDA approval in December 2025 for an ORLADEYO pellet formulation for children aged 2 to under 12 with HAE, completed the acquisition of Astria Therapeutics in January 2026 to add the Phase 3 HAE antibody navenibart, and reaffirmed 2026 revenue guidance of $625 million to $645 million for ORLADEYO while investing in its expanded HAE franchise and broader rare-disease pipeline.
Non-GAAP figures show core operations strengthening, with 2025 revenues rising 45% to $592.9 million and operating profit up 198% to $214.2 million, alongside disciplined R&D spending and higher commercial outlays to support ORLADEYO’s growth. Positive long-term interim data from the ALPHA-SOLAR trial showed durable, high-level HAE attack suppression with navenibart and underpinned an ongoing Phase 3 program expected to support a regulatory filing by the end of 2027, reinforcing BioCryst’s bid to consolidate its leadership position in HAE prophylaxis.
The most recent analyst rating on (BCRX) stock is a Buy with a $17.00 price target. To see the full list of analyst forecasts on BioCryst stock, see the BCRX Stock Forecast page.
Spark’s Take on BCRX Stock
According to Spark, TipRanks’ AI Analyst, BCRX is a Neutral.
Overall score reflects weak underlying financial health (negative equity, negative cash flow) and bearish technicals (below major moving averages with negative MACD). These are partially offset by a strong and improving operating narrative from the latest earnings call, including raised ORLADEYO guidance and improved non-GAAP profitability.
To see Spark’s full report on BCRX stock, click here.
More about BioCryst
BioCryst Pharmaceuticals, Inc. is a global biotechnology company focused on developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. Its lead product ORLADEYO (berotralstat) is the first oral, once-daily plasma kallikrein inhibitor, and the company is advancing a pipeline of oral small-molecule and injectable protein therapeutics targeting niche rare-disease markets.
In 2025, BioCryst achieved its first full-year profitability, as total revenues nearly doubled to $874.8 million and ORLADEYO net revenue climbed 38% to $601.8 million despite the October sale of its European ORLADEYO business to Neopharmed Gentili. The company streamlined operations with that divestiture, gained FDA approval in December 2025 for an ORLADEYO pellet formulation for children aged 2 to under 12 with HAE, completed the acquisition of Astria Therapeutics in January 2026 to add the Phase 3 HAE antibody navenibart, and reaffirmed 2026 revenue guidance of $625 million to $645 million for ORLADEYO while investing in its expanded HAE franchise and broader rare-disease pipeline.
Non-GAAP figures show core operations strengthening, with 2025 revenues rising 45% to $592.9 million and operating profit up 198% to $214.2 million, alongside disciplined R&D spending and higher commercial outlays to support ORLADEYO’s growth. Positive long-term interim data from the ALPHA-SOLAR trial showed durable, high-level HAE attack suppression with navenibart and underpinned an ongoing Phase 3 program expected to support a regulatory filing by the end of 2027, reinforcing BioCryst’s bid to consolidate its leadership position in HAE prophylaxis.
Average Trading Volume: 4,078,363
Technical Sentiment Signal: Sell
Current Market Cap: $1.89B
For detailed information about BCRX stock, go to TipRanks’ Stock Analysis page.
